Comparative Pharmacology
Head-to-head clinical analysis: DIPHENYLAN SODIUM versus SPRITAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENYLAN SODIUM versus SPRITAM.
DIPHENYLAN SODIUM vs SPRITAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.
Spritam is a levetiracetam formulation; levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A) to modulate neurotransmitter release, reducing neuronal excitability.
100 mg orally every 8 hours
SPRITAM is not a standard formulation; levetiracetam immediate-release: 500 mg PO BID, titrated to 1000 mg PO BID (max 1500 mg PO BID). For extended-release (Keppra XR): 1000 mg PO once daily, titrated to 2000 mg PO once daily.
None Documented
None Documented
22 hours (range 10-34 hours); prolonged in hepatic impairment or with CYP inhibitors; correlates with time to steady state (~5 days).
Terminal half-life: 6–8 hours; clinical context: requires twice-daily dosing for stable serum concentrations
Primarily hepatic metabolism via CYP450; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20-30% of metabolites.
Renal: 66% unchanged; hepatic metabolism: 24% (inactive metabolites); fecal: negligible (<1%)
Category C
Category C
Antiepileptic
Antiepileptic